English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background: Human Epidermal growth factor Receptor type 2 (HER2) is over expressed in 20.0-30.0% of breast cancers and is currently evaluated histopathologically. Immunohistochemistry and fluorescence in situ hybridization require invasive enucleation of the tumor tissue and may be affected by heterogeneity. Serum marker tests are more objective because of the uniformity of the study material. Serum HER2 levels are important for breast cancer care. However, the clinical utility of serum HER2 testing is unclear. We evaluated serum HER2 as a marker of therapeutic response in breast cancer. Methods: Serum HER2 levels were measured in 64 tissue HER2-positive breast cancer patients during routine care. Relationships between serum HER2 levels, clinical stage, tumor diameter, therapeutic response, and Distant Metastasis (DM) were analyzed. Results: Serum HER2 levels correlated with therapeutic response. An association was observed between serum HER2 levels and tumor diameter. Serum HER2 levels were significantly higher in patients with DM than in those without DM. Conclusions: Serum HER2 levels are associated with therapeutic response, tumor diameter, and DM. We confirm the clinical utility of serum HER2 testing for monitoring therapeutic response and disease progression in patients with breast cancer.

international journal of cancer and clinical research

Clinical Utility of Serum Human Epidermal Growth Factor Receptor Type 2 Testing as a Marker of Therapeutic Response In Tissue HER2-Positive Breast Cancer Patients